+

WO2003076658A3 - A susceptibility gene for late-onset idiopathic parkinson's disease - Google Patents

A susceptibility gene for late-onset idiopathic parkinson's disease

Info

Publication number
WO2003076658A3
WO2003076658A3 PCT/IB2002/004276 IB0204276W WO03076658A3 WO 2003076658 A3 WO2003076658 A3 WO 2003076658A3 IB 0204276 W IB0204276 W IB 0204276W WO 03076658 A3 WO03076658 A3 WO 03076658A3
Authority
WO
WIPO (PCT)
Prior art keywords
park8
disease
agents
parkinson
late
Prior art date
Application number
PCT/IB2002/004276
Other languages
French (fr)
Other versions
WO2003076658A2 (en
Inventor
Andrew A Hicks
Original Assignee
Decode Genetics Ehf
Andrew A Hicks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf, Andrew A Hicks filed Critical Decode Genetics Ehf
Priority to AU2002339230A priority Critical patent/AU2002339230A1/en
Publication of WO2003076658A2 publication Critical patent/WO2003076658A2/en
Publication of WO2003076658A3 publication Critical patent/WO2003076658A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Methods of diagnosis of susceptibility to Parkinson's disease; assays for agents that alter the activity of a Parkinson's disease polypeptide, (e.g., PARK8 polypeptide) or which identify PARK8 binding agents, and the agents or binding agents identified by the assays; PARK8 therapeutic agents, including the PARK8 nucleic acids, PARK8 polypeptides, or agents that alter the activity of an PARK8 polypeptides; pharmaceutical compositions comprising the PARK8 therapeutic agents; as well as methods of therapy of Parkinson' s disease are disclosed.
PCT/IB2002/004276 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease WO2003076658A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002339230A AU2002339230A1 (en) 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36322002P 2002-03-08 2002-03-08
US60/363,220 2002-03-08

Publications (2)

Publication Number Publication Date
WO2003076658A2 WO2003076658A2 (en) 2003-09-18
WO2003076658A3 true WO2003076658A3 (en) 2003-12-31

Family

ID=27805269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004276 WO2003076658A2 (en) 2002-03-08 2002-10-14 A susceptibility gene for late-onset idiopathic parkinson's disease

Country Status (2)

Country Link
AU (1) AU2002339230A1 (en)
WO (1) WO2003076658A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156845B2 (en) 2012-06-29 2015-10-13 Pfizer Inc. 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361258A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease
DE102004014841B4 (en) 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome
CN103175972B (en) * 2005-10-21 2015-05-20 株式会社芳珂 Atopic dermatitis marker and technique of using same
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
UA126231C2 (en) 2016-06-16 2022-09-07 Деналі Терапьютікс Інк. PYRIMIDINE-2-YLAMINO-1H-PYRAZOLES AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATE DISEASES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072777A2 (en) * 2000-03-13 2001-10-04 Incyte Genomics, Inc. Human transcription factors
WO2001092576A1 (en) * 2000-05-26 2001-12-06 Duke University Methods of screening for parkinson's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072777A2 (en) * 2000-03-13 2001-10-04 Incyte Genomics, Inc. Human transcription factors
WO2001092576A1 (en) * 2000-05-26 2001-12-06 Duke University Methods of screening for parkinson's disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HUM [online] EMBL; 26 March 2000 (2000-03-26), WRAY, P.: "Human DNA sequence from clone RP11-296A18 on chromosome 1", XP002258314, retrieved from EBI Database accession no. AL162430 *
DATABASE SWALL [online] 28 February 2003 (2003-02-28), SEKI ET AL.: "RING finger protein 11 (Sid1669) (CGI-123)", XP002258315, retrieved from EBI accession no. RN11_HUMAN Database accession no. Q9Y3C5 *
HICKS ET AL.: "A susceptibility gene for late-onset idiopathic Parkinson's disease", ANN. NEUROL., vol. 52, no. 5, November 2002 (2002-11-01), pages 549 - 555, XP002258313 *
LI ET AL.: "Age at onset in two common neurodegenerative diseases is genetically controlled", AM. J. HUM. GENET., vol. 70, 1 March 2002 (2002-03-01), pages 985 - 993, XP002258312 *
SEKI N ET AL: "Cloning and expression profile of mouse and human genes, Rnf11/RNF11, encoding a novel RING-H2 finger protein", BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1489, no. 2-3, 23 December 1999 (1999-12-23), pages 421 - 427, XP004275554, ISSN: 0167-4781 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156845B2 (en) 2012-06-29 2015-10-13 Pfizer Inc. 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Also Published As

Publication number Publication date
AU2002339230A1 (en) 2003-09-22
WO2003076658A2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2005077042A3 (en) Albumin fusion proteins
CA2257133A1 (en) Human dnase i hyperactive variants
WO2005040418A3 (en) Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
WO2004006838A3 (en) Novel kinases
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
WO2001064877A3 (en) Human schizophrenia gene
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001064876A3 (en) Human schizophrenia gene
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
WO2000005373A9 (en) Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2002070559A3 (en) Nuclear hormone receptor ligand binding domains
IL151211A0 (en) Compositions useful for regulating parkin gene activity
WO2007134907A3 (en) Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
WO2005054426A3 (en) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
WO2002098454A3 (en) Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2004009633A8 (en) Serotonin receptor
WO2001030991A3 (en) Human narcolepsy gene
WO2006000464A3 (en) Method for discovering pain-relevant substances using pain-relevant proteins
WO2004003011A3 (en) Nuclear hormone receptor
WO2002083726A3 (en) A novel zinc finger protein and uses thereof
WO2002070560A3 (en) Nuclear hormone receptor ligand binding domain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载